Douglas Lane & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Douglas Lane & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,860	Closed	-$270K	–	214
2016 Q3	$270K	Sell	5,860 -775	-12%	-$40.4K	0.01%	192
2016 Q2	$333K	Buy	6,635 +2,414	+57%	+$129K	0.01%	190
2016 Q1	$226K	Buy	+4,221	New	+$248K	0.01%	204

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Douglas Lane & Associates's TEVA Position: Q4 2016 in Review

Douglas Lane & Associates sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 5,860 shares — an estimated $270K sold.

Douglas Lane & Associates first reported a position in TEVA in Q1 2016 and held it in 3 quarters. The position peaked at $333K in Q2 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Douglas Lane & Associates reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Douglas Lane & Associates sold 5,860 Teva Pharmaceuticals shares in Q4 2016, an estimated $270K.
Douglas Lane & Associates first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 3 quarters.
Douglas Lane & Associates's Teva Pharmaceuticals position peaked at $333K in Q2 2016.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Douglas Lane & Associates's 13F filing for Q4 2016, filed 17 Jan 2017.